打开APP

Shire耗资$2.6亿收购Lumena制药 获2种肝脏病药物

  1. Lumenta
  2. Shire
  3. 罕见病

来源:生物谷 2014-05-13 08:43

Shire耗资2.6亿美元收购Lumena制药,获得2种罕见病药物。

2014年5月13日讯 /生物谷BIOON/ --英国制药商Shire制药5月12日宣布,将至少耗资2.6亿美元收购美国Lumena制药,该笔交易将使Shire获得2种罕见肝病药物,增强该公司罕见病产品组合,并加强肠胃病业务。目前,Shire自身已吸引了艾尔健(Allergan)的兴趣。

Shire将帮助Lumena公司推进2个肝脏药物进入III期临床开发以及上市。这2个药物是3年前从辉瑞和赛诺菲收购获得。第一种药物目前正处于7个II期研究,调查用于由高水平胆汁酸导致的4种不同疾病的治疗。第二种药物开发用于非酒精性脂肪肝(NASH)的治疗。Shire将支付一笔2.6亿美元现金的预付款,同时将支付相关的临床里程碑款项。(生物谷Bioon.com)

英文原文:UPDATE 1-Shire buys Lumena Pharma for at least $260 mln

Shire says deal boosts rare diseases portfolio

* Lumena received multiple approaches

* Says Shire will help it take liver drugs to market (Adds detail, Lumena CEO comments)

By Paul Sandle

LONDON, May 12 (Reuters) - London-listed drugmaker Shire has bought San Diego-based biopharmaceuticals company Lumena Pharmaceuticals for at least $260 million in a deal that gives it promising drugs that could be used to treat rare liver diseases.

In the latest in a wave of pharmaceuticals sector consolidation, Shire, which itself has reportedly attracted the interest of Allergan Inc, said the Lumina deal would add to its rare diseases portfolio and strengthen its gastrointestinal business.

Lumena CEO Mike Grey, meanwhile, said that Shire would help his company take its two liver drugs through the final stages of development and into the market.

The company acquired the drugs three years ago from Pfizer and Sanofi, which were devloping them for different applications before putting them on the shelf.

"We identified some new biology that showed some potential applications for these compounds in treating liver disease," Grey said in a telephone interview on Monday.

The first compound was in seven Phase II studies in four different diseases caused by the accumulation of high levels of bile acids that ultimately result in liver failure, he said.

The four diseases have a prevalence between one person in 100,000 and 30 people in 100,000, he said.

The second compound was in development for the treatment of nonalcoholic steatohepatitis (NASH), a common and often "silent" liver disease characterised by fat deposits in the liver and inflammation that can progress to significant fibrosis, the company said.

Grey said the company had received a number of approaches and was also considering an initial public offering before accepting Shire's offer.

He said the group's team of 17 researchers would continue working on the development of the drugs and would share in some of the proceeds of the deal, along with the company's other backers, including founder Pappas Ventures and Alta Partners, RiverVest Venture Partners, New Enterprise Associates, Adage Capital Management and RA Capital Management

Shire said it would make an upfront payment of $260 million in cash, plus a payment for net cash at closing, as well as near-term contingent milestone payments related to ongoing clinical trials.

The company added that does not expect the acquisition to result in a change to its previously stated earnings guidance for 2014.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->